Please assess the completion status of the following clinical trial:

Trial Title: A Study of Linifanib (ABT-869) in Combination With Carboplatin/Paclitaxel in Japanese Subjects With Non-Small Cell Lung Cancer (NSCLC)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* The subject must be 20 and older years of age.~* The subject must have cytologically or histologically confirmed non-squamous NSCLC. Subjects may have a mixed histology but must be predominantly non-squamous to be eligible.~* The subject must have advanced or metastatic (Stage IV \[According to American Joint Committee on Cancer (AJCC) staging manual, 7th edition\]) disease that is not amenable to surgical resection or radiation with curative intent.~* The subject must have not received prior chemotherapy for NSCLC.~* The subject has measurable disease, defined as at least 1 unidimensionally measurable lesion on a CT scan as defined by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.~* The subject has an Easter Cooperative Oncology Group (ECOG) Performance Score of 0-1.~* The subject must have adequate bone marrow, renal and hepatic function.~Exclusion Criteria~* The subject has hypersensitivity to paclitaxel or to other drugs formulated with polyethoxylated castor oil (Cremophor).~* The subject has received any anti-cancer therapy for treatment of NSCLC including investigational agents, immunotherapy, traditional Chinese medicine/herbal remedies, hormonal, targeted agents (i.e., erlotinib, imatinib), biologic therapy or cytotoxic chemotherapy (i.e., alkylating agents, microtubule inhibitors, antimetabolites).~* The subject has a history of another active cancer within the past 5 years except cervical cancer in situ, in situ carcinoma of the bladder, squamous cell or basal cell carcinoma of the skin.~* The subject has active ulcerative colitis, Crohn's disease, celiac disease or any other conditions that interfere with absorption.~* The subject has a medical condition, which in the opinion of the study investigator places them at an unacceptably high risk for toxicities.~* The subject is pregnant or breast feeding.~* The subject has NSCLC with a predominant squamous cell histology.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: EXPERIMENTAL): None
- Arm B (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).